Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation

Fundamental and Clinical Pharmacology

Volumn 27, Issue 4, 2013, Pages 434-442

  Chu, Céline ^a   Noël Hudson, Marie Sophie ^b   Boige, Valérie ^c   Goéré, Diane ^c   Marion, Sylvie ^a   Polrot, Mélanie ^c   Bigot, Ludovic ^c   Gonin, Patrick ^c   Farinotti, Robert ^b   Bonhomme Faivre, Laurence ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b EA4123   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Colorectal cancer; Everolimus; KRAS mutation; Lapatinib; P glycoprotein

Indexed keywords

EVEROLIMUS; K RAS PROTEIN; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GASTROINTESTINAL TOXICITY; GENE MUTATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; MUTATION; P-GLYCOPROTEINS; QUINAZOLINES; RAS PROTEINS; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879553997     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01035.x     Document Type: Article

References (31)

1. Lamoril J., Ameziane N., Deybach J.C., Bouizegarène P., Bogard M.KRAS and colorectal cancer: an important step to the personalized medicine. IBS (2009) 24 196-209.
2. Spano J.P., Milano G., Vignot S., Khayat D.Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit. Rev. Oncol. Hematol. (2008) 66 21-30.
3. Motzer R.J., Escudier B., Oudard S. et al.Efficacity of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 372 449-456.
4. Coiffier B., Ribrag V.Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk. Lymphoma (2009) 8 1-15.
5. Yuan R., Kay A., Berg W.J., Lebwohl D.J.Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J. Hematol. Oncol. (2009) 2 45.
6. Zhang Y.J., Dai Q., Sun D.F. et al.mTOR signaling pathway is a Target for the treatment of colorectal cancer. Ann. Surg. Oncol. (2009) 16 2617-2628.
7. Geyer C.E., Forster J., Lindquist D. et al.Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. (2006) 355 2733-2743.
8. Hegde P.S., Rusnak D., Bertiaux M. et al.Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol. Cancer Ther. (2007) 6 1629-1640.
9. Essapen S., Thomas H., Green M. et al.The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int. J. Oncol. (2004) 24 241-248.
10. Kruszewski W.J., Rzepko R., Ciesielski M. et al.Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis. Markers (2010) 29 207-212.
11. Finocchiaro G., Cappuzzo F., Jänne P.A. et al.EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J. Clin. Oncol. (2007) 25 4021.
12. Kurtze I., Sonnemann J., Beck J.F.KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. Oncol. Rep. (2011) 25 1021-1029.
13. Schinkel A.H., Mayer U., Wagenaar E. et al.Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug - transporting) P-glycoprotein. Proc. Natl Acad. Sci. USA (1997) 94 4028-4033.
14. Vasiliou V., Vasiliou K., Nebert D.W.Human ATP-binding cassette (ABC) transporter family. Hum. Genomics (2009) 3 281-290.
15. Hosten B., Abbara C., Petit B. et al.Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice. Drug Metab. Dispos. (2008) 36 695-701.
16. Molina J.R., Kaufmann S.C., Reid J. et al.Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin. Cancer Res. (2008) 14 7900-7908.
17. Laplante A., Demeule M., Murphy G.F., Béliveau R.Interaction of immunosuppressive agents rapamycin and its analogue SDZ-RAD with endothelial P-gp. Transplant. Proc. (2002) 34 3393-3395.
18. Kirchner G.I., Meier-Wiedenbach I., Manns M.P.Clin pharmacokinet of everolimus. Clin. Pharmacokinet. (2004) 43 83-95.
19. Kovarik J.M., Beyer D., Bizot M.N., Jiang Q., Allison M.J., Schmouder R.L.Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br. J. Clin. Pharmacol. (2005) 60 434-437.
20. Collins D., O'Connor R., O'Donovan N., Clynes M., Crown J.Lapatinib inhibits P-glycoprotein (P-GP) and synergistically enhances taxane cytotoxicity in PgP+ cell lines. Ann. Oncol. (2006) 17 57.
21. Polli J.W., Humphreys J.E., Harmon K.A. et al.The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4 quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos. (2008) 36 695-701.
22. Chu C., Abbara C., Noël-Hudson M.S. et al.Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. Biochem. Pharmacol. (2009) 77 1629-1634.
23. O'Reilly T., McSheehy P.M.Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals. Transl. Oncol. (2010) 3 65-79.
24. O'Reilly T., McSheehy P.M., Kawai R. et al.Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother. Pharmacol. (2010) 65 625-639.
25. Siegel-Lakhai W.S., Beijnen J.H., Vervenne W.L. et al.Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors. Clin. Cancer Res. (2007) 13 4495-4502.
26. Green E.L.Biology of the laboratory mouse. Mc Graw Hill, New York, USA, 1966.
27. Yang J.M., Sullivan G.F., Hait W.N.Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem. Pharmacol. (1997) 53 1597-1604.
28. Rohlff C., Glazer R.I.Regulation of multidrug resistance through the CAMP and EGF signalling pathways. Cell. Signal. (1995) 7 431-443.
29. Hirsch-Ernst K.I., Ziemann C., Schmitz-Salue C., Foth H., Kahl G.F.Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem. Biophys. Res. Commun. (1995) 215 179-185.
30. Bianco R., Garofalo S., Rosa R. et al.Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br. J. Cancer (2008) 98 923-930.
31. Vazquez-Martin A., Oliveras-Ferraros C., Colomer R., Brunet J., Menendez J.A.Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann. Oncol. (2008) 19 1097-1109.